{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T23:56:07Z","timestamp":1794009367787,"version":"4.8.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,4,30]],"date-time":"2022-04-30T00:00:00Z","timestamp":1651276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,4,30]],"date-time":"2022-04-30T00:00:00Z","timestamp":1651276800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1007\/s40257-022-00679-y","type":"journal-article","created":{"date-parts":[[2022,4,30]],"date-time":"2022-04-30T05:02:49Z","timestamp":1651294969000},"page":"433-447","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":91,"title":["Time to Relapse After Discontinuing Systemic Treatment for Psoriasis: A Systematic Review"],"prefix":"10.1007","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2625-0628","authenticated-orcid":false,"given":"Marie","family":"Masson Regnault","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Shourick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatma","family":"Jendoubi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Tauber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carle","family":"Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,30]]},"reference":[{"key":"679_CR1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011535.pub3","volume":"1","author":"E Sbidian","year":"2020","unstructured":"Sbidian E, Chaimani A, Afach S, Doney L, Dressler C, Hua C, Mazaud C, Phan C, Hughes C, Riddle D, Naldi L, Garcia-Doval I, Le Cleach L. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev. 2020;1: 011535. https:\/\/doi.org\/10.1002\/14651858.CD011535.pub3.","journal-title":"Cochrane Database Syst Rev"},{"key":"679_CR2","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.jaci.2017.07.004","volume":"140","author":"JE Hawkes","year":"2017","unstructured":"Hawkes JE, Chan TC, Krueger JG. Psoriasis pathogenesis and the development of novel targeted immune therapies. J Allergy Clin Immunol. 2017;140:645\u201353. https:\/\/doi.org\/10.1016\/j.jaci.2017.07.004.","journal-title":"J Allergy Clin Immunol"},{"key":"679_CR3","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/S0140-6736(14)61909-7","volume":"386","author":"W-H Boehncke","year":"2015","unstructured":"Boehncke W-H, Sch\u00f6n MP. Psoriasis. Lancet. 2015;386:983\u201394. https:\/\/doi.org\/10.1016\/S0140-6736(14)61909-7.","journal-title":"Lancet"},{"key":"679_CR4","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1007\/s00403-015-1593-8","volume":"307","author":"K Reich","year":"2015","unstructured":"Reich K, Mrowietz U, Radtke MA, Thaci D, Rustenbach SJ, Spehr C, Augustin M. Drug safety of systemic treatments for psoriasis: results from The German Psoriasis Registry PsoBest. Arch Dermatol Res. 2015;307:875\u201383. https:\/\/doi.org\/10.1007\/s00403-015-1593-8.","journal-title":"Arch Dermatol Res"},{"key":"679_CR5","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1111\/bjd.16102","volume":"178","author":"A Egeberg","year":"2018","unstructured":"Egeberg A, Ottosen MB, Gniadecki R, Broesby-Olsen S, Dam TN, Bryld LE, Rasmussen MK, Skov L. Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis. Br J Dermatol. 2018;178:509\u201319. https:\/\/doi.org\/10.1111\/bjd.16102.","journal-title":"Br J Dermatol"},{"key":"679_CR6","first-page":"706","volume":"14","author":"K Papp","year":"2015","unstructured":"Papp K, Gottlieb AB, Naldi L, Pariser D, Ho V, Goyal K, Fakharzadeh S, Chevrier M, Calabro S, Langholff W, Krueger G. Safety surveillance for ustekinumab and other psoriasis treatments from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). J Drugs Dermatol. 2015;14:706\u201314.","journal-title":"J Drugs Dermatol"},{"key":"679_CR7","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1111\/jdv.14387","volume":"31","author":"M Masson Regnault","year":"2017","unstructured":"Masson Regnault M, Konstantinou M-P, Khemis A, Poulin Y, Bourcier M, Amelot F, Bula\u00ef Livideanu C, Paul C. Early relapse of psoriasis after stopping brodalumab: a retrospective cohort study in 77 patients. J Eur Acad Dermatol Venereol. 2017;31:1491\u20136. https:\/\/doi.org\/10.1111\/jdv.14387.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"679_CR8","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1111\/j.1346-8138.2010.01041.x","volume":"38","author":"Y Okubo","year":"2011","unstructured":"Okubo Y, Natsume S, Usui K, Amaya M, Tsuboi R. Low-dose, short-term ciclosporin (Neoral\u00ae) therapy is effective in improving patients\u2019 quality of life as assessed by Skindex-16 and GHQ-28 in mild to severe psoriasis patients. J Dermatol. 2011;38:465\u201372. https:\/\/doi.org\/10.1111\/j.1346-8138.2010.01041.x.","journal-title":"J Dermatol"},{"key":"679_CR9","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1056\/NEJMoa021359","volume":"349","author":"VMR Heydendael","year":"2003","unstructured":"Heydendael VMR, Spuls PI, Opmeer BC, de Borgie CAJM, Reitsma JB, Goldschmidt WFM, Bossuyt PMM, Bos JD, de Rie MA. Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N Engl J Med. 2003;349:658\u201365. https:\/\/doi.org\/10.1056\/NEJMoa021359.","journal-title":"N Engl J Med"},{"key":"679_CR10","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1001\/archderm.1995.01690190043008","volume":"131","author":"CN Ellis","year":"1995","unstructured":"Ellis CN, Fradin MS, Hamilton TA, Voorhees JJ. Duration of remission during maintenance cyclosporine therapy for psoriasis. Relationship to maintenance dose and degree of improvement during initial therapy. Arch Dermatol. 1995;131:791\u20135.","journal-title":"Arch Dermatol"},{"key":"679_CR11","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1046\/j.1365-2133.1999.02977.x","volume":"141","author":"VC Ho","year":"1999","unstructured":"Ho VC, Griffiths CE, Albrecht G, Vanaclocha F, Le\u00f3n-Dorantes G, Atakan N, Reitamo S, Ohannesson A, M\u00f8rk NJ, Clarke P, Pfister P, Paul C. Intermittent short courses of cyclosporin (Neoral(R)) for psoriasis unresponsive to topical therapy: a 1-year multicentre, randomized study The PISCES Study Group. Br J Dermatol. 1999;141:283\u201391. https:\/\/doi.org\/10.1046\/j.1365-2133.1999.02977.x.","journal-title":"Br J Dermatol"},{"key":"679_CR12","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1080\/09546630500472838","volume":"17","author":"KB Gordon","year":"2006","unstructured":"Gordon KB, Gottlieb AB, Leonardi CL, Elewski BE, Wang A, Jahreis A, Zitnik R. Clinical response in psoriasis patients discontinued from and then reinitiated on etanercept therapy. J Dermatolog Treat. 2006;17:9\u201317. https:\/\/doi.org\/10.1080\/09546630500472838.","journal-title":"J Dermatolog Treat"},{"key":"679_CR13","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.jaad.2006.09.002","volume":"56","author":"A Moore","year":"2007","unstructured":"Moore A, Gordon KB, Kang S, Gottlieb A, Freundlich B, Xia HA, Stevens SR. A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis. J Am Acad Dermatol. 2007;56:598\u2013603. https:\/\/doi.org\/10.1016\/j.jaad.2006.09.002.","journal-title":"J Am Acad Dermatol"},{"key":"679_CR14","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1111\/j.1365-2133.2009.09238.x","volume":"161","author":"J-P Ortonne","year":"2009","unstructured":"Ortonne J-P, Ta\u00efeb A, Ormerod AD, Robertson D, Foehl J, Pedersen R, Molta C, Freundlich B. Patients with moderate-to-severe psoriasis recapture clinical response during re-treatment with etanercept. Br J Dermatol. 2009;161:1190\u20135. https:\/\/doi.org\/10.1111\/j.1365-2133.2009.09238.x.","journal-title":"Br J Dermatol"},{"key":"679_CR15","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1056\/NEJMoa0810652","volume":"362","author":"CEM Griffiths","year":"2010","unstructured":"Griffiths CEM, Strober BE, van de Kerkhof P, Ho V, Fidelus-Gort R, Yeilding N, Guzzo C, Xia Y, Zhou B, Li S, Dooley LT, Goldstein NH, Menter A, ACCEPT Study Group. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med. 2010;362:118\u201328. https:\/\/doi.org\/10.1056\/NEJMoa0810652.","journal-title":"N Engl J Med"},{"key":"679_CR16","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.jaad.2007.09.010","volume":"58","author":"A Menter","year":"2008","unstructured":"Menter A, Tyring SK, Gordon K, Kimball AB, Leonardi CL, Langley RG, Strober BE, Kaul M, Gu Y, Okun M, Papp K. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol. 2008;58:106\u201315. https:\/\/doi.org\/10.1016\/j.jaad.2007.09.010.","journal-title":"J Am Acad Dermatol"},{"key":"679_CR17","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1111\/j.1365-2133.2010.10139.x","volume":"164","author":"K Papp","year":"2011","unstructured":"Papp K, Crowley J, Ortonne J-P, Leu J, Okun M, Gupta SR, Gu Y, Langley RG. Adalimumab for moderate to severe chronic plaque psoriasis: efficacy and safety of retreatment and disease recurrence following withdrawal from therapy. Br J Dermatol. 2011;164:434\u201341. https:\/\/doi.org\/10.1111\/j.1365-2133.2010.10139.x.","journal-title":"Br J Dermatol"},{"key":"679_CR18","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.jaad.2004.02.021","volume":"51","author":"AB Gottlieb","year":"2004","unstructured":"Gottlieb AB, Evans R, Li S, Dooley LT, Guzzo CA, Baker D, Bala M, Marano CW, Menter A. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol. 2004;51:534\u201342. https:\/\/doi.org\/10.1016\/j.jaad.2004.02.021.","journal-title":"J Am Acad Dermatol"},{"key":"679_CR19","doi-asserted-by":"publisher","first-page":"31.e1\u201315","DOI":"10.1016\/j.jaad.2006.07.017","volume":"56","author":"A Menter","year":"2007","unstructured":"Menter A, Feldman SR, Weinstein GD, Papp K, Evans R, Guzzo C, Li S, Dooley LT, Arnold C, Gottlieb AB. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2007;56:31.e1-15. https:\/\/doi.org\/10.1016\/j.jaad.2006.07.017.","journal-title":"J Am Acad Dermatol"},{"key":"679_CR20","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1111\/j.1365-2133.2012.10941.x","volume":"167","author":"K Reich","year":"2012","unstructured":"Reich K, Ortonne J-P, Gottlieb AB, Terpstra IJ, Coteur G, Tasset C, Mease P. Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab\u2019 certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension. Br J Dermatol. 2012;167:180\u201390. https:\/\/doi.org\/10.1111\/j.1365-2133.2012.10941.x.","journal-title":"Br J Dermatol"},{"key":"679_CR21","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1111\/bjd.12112","volume":"168","author":"P Rich","year":"2013","unstructured":"Rich P, Sigurgeirsson B, Thaci D, Ortonne J-P, Paul C, Schopf RE, Morita A, Roseau K, Harfst E, Guettner A, Machacek M, Papavassilis C. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study. Br J Dermatol. 2013;168:402\u201311. https:\/\/doi.org\/10.1111\/bjd.12112.","journal-title":"Br J Dermatol"},{"key":"679_CR22","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jaad.2015.04.011","volume":"73","author":"U Mrowietz","year":"2015","unstructured":"Mrowietz U, Leonardi CL, Girolomoni G, Toth D, Morita A, Balki SA, Szepietowski JC, Regnault P, Thurston H, Papavassilis C, SCULPTURE Study Group. Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: a randomized, double-blind, noninferiority trial (SCULPTURE). J Am Acad Dermatol. 2015;73:27-36.e1. https:\/\/doi.org\/10.1016\/j.jaad.2015.04.011.","journal-title":"J Am Acad Dermatol"},{"key":"679_CR23","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1111\/bjd.15656","volume":"177","author":"A Blauvelt","year":"2017","unstructured":"Blauvelt A, Reich K, Warren RB, Szepietowski JC, Sigurgeirsson B, Tyring SK, Messina I, Bhosekar V, Oliver J, Papavassilis C, Frueh J, Langley RGB. Secukinumab re-initiation achieves regain of high response levels in patients who interrupt treatment for moderate to severe plaque psoriasis. Br J Dermatol. 2017;177:879\u201381. https:\/\/doi.org\/10.1111\/bjd.15656.","journal-title":"Br J Dermatol"},{"key":"679_CR24","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1056\/NEJMoa1512711","volume":"375","author":"KB Gordon","year":"2016","unstructured":"Gordon KB, Blauvelt A, Papp KA, Langley RG, Luger T, Ohtsuki M, Reich K, Amato D, Ball SG, Braun DK, Cameron GS, Erickson J, Konrad RJ, Muram TM, Nickoloff BJ, Osuntokun OO, Secrest RJ, Zhao F, Mallbris L, Leonardi CL, UNCOVER-1 Study Group, UNCOVER-2 Study Group, UNCOVER-3 Study Group. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med. 2016;375:345\u201356. https:\/\/doi.org\/10.1056\/NEJMoa1512711.","journal-title":"N Engl J Med"},{"key":"679_CR25","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1111\/jdv.14163","volume":"31","author":"A Blauvelt","year":"2017","unstructured":"Blauvelt A, Papp KA, Sofen H, Augustin M, Yosipovitch G, Katoh N, Mrowietz U, Ohtsuki M, Poulin Y, Shrom D, Burge R, See K, Mallbris L, Gordon KB. Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis. J Eur Acad Dermatol Venereol. 2017;31:1004\u201313. https:\/\/doi.org\/10.1111\/jdv.14163.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"679_CR26","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/bjd.14493","volume":"175","author":"KA Papp","year":"2016","unstructured":"Papp KA, Reich K, Paul C, Blauvelt A, Baran W, Bolduc C, Toth D, Langley RG, Cather J, Gottlieb AB, Tha\u00e7i D, Krueger JG, Russell CB, Milmont CE, Li J, Klekotka PA, Kricorian G, Nirula A. A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2016;175:273\u201386. https:\/\/doi.org\/10.1111\/bjd.14493.","journal-title":"Br J Dermatol"},{"key":"679_CR27","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1111\/bjd.19132","volume":"183","author":"K Papp","year":"2020","unstructured":"Papp K, Menter A, Leonardi C, Soung J, Weiss S, Pillai R, Jacobson A. Long-term efficacy and safety of brodalumab in psoriasis through 120 weeks and after withdrawal and retreatment: subgroup analysis of a randomized phase III trial (AMAGINE-1). Br J Dermatol. 2020;183:1037\u201348. https:\/\/doi.org\/10.1111\/bjd.19132.","journal-title":"Br J Dermatol"},{"key":"679_CR28","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1016\/S0140-6736(08)60725-4","volume":"371","author":"CL Leonardi","year":"2008","unstructured":"Leonardi CL, Kimball AB, Papp KA, Yeilding N, Guzzo C, Wang Y, Li S, Dooley LT, Gordon KB, PHOENIX 1 Study Investigators. Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008;371:1665\u201374. https:\/\/doi.org\/10.1016\/S0140-6736(08)60725-4.","journal-title":"Lancet"},{"key":"679_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jamadermatol.2020.0723","volume":"156","author":"A Blauvelt","year":"2020","unstructured":"Blauvelt A, Leonardi CL, Gooderham M, Papp KA, Philipp S, Wu JJ, Igarashi A, Flack M, Geng Z, Wu T, Camez A, Williams D, Langley RG. Efficacy and safety of continuous risankizumab therapy vs treatment withdrawal in patients with moderate to severe plaque psoriasis. JAMA Dermatol. 2020;156:1\u201311. https:\/\/doi.org\/10.1001\/jamadermatol.2020.0723.","journal-title":"JAMA Dermatol"},{"key":"679_CR30","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1111\/bjd.18484","volume":"182","author":"AB Kimball","year":"2020","unstructured":"Kimball AB, Papp KA, Reich K, Gooderham M, Li Q, Cichanowitz N, La Rosa C, Blauvelt A. Efficacy and safety of tildrakizumab for plaque psoriasis with continuous dosing, treatment interruption, dose adjustments and switching from etanercept: results from phase III studies. Br J Dermatol. 2020;182:1359\u201368. https:\/\/doi.org\/10.1111\/bjd.18484.","journal-title":"Br J Dermatol"},{"key":"679_CR31","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16964","author":"RB Warren","year":"2020","unstructured":"Warren RB, Carrascosa JM, Fumero E, Schoenenberger A, Lebwohl MG, Szepietowski JC, Reich K. Time to relapse after tildrakizumab withdrawal in patients with moderate-to-severe psoriasis who were responders at week 28: post hoc analysis through 64 weeks from reSURFACE 1 trial. J Eur Acad Dermatol Venereol. 2020. https:\/\/doi.org\/10.1111\/jdv.16964.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"679_CR32","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17124","author":"W Cantrell","year":"2021","unstructured":"Cantrell W, Lee P, Mendelsohn AM, Rozzo SJ, Liao W. Efficacy and safety of tildrakizumab 100 mg for plaque psoriasis in patients randomized to treatment continuation vs treatment withdrawal with retreatment upon relapse in reSURFACE 1. J Eur Acad Dermatol Venereol. 2021. https:\/\/doi.org\/10.1111\/jdv.17124.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"679_CR33","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.jaad.2016.11.042","volume":"76","author":"K Reich","year":"2017","unstructured":"Reich K, Armstrong AW, Foley P, Song M, Wasfi Y, Randazzo B, Li S, Shen Y-K, Gordon KB. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol. 2017;76:418\u201331. https:\/\/doi.org\/10.1016\/j.jaad.2016.11.042.","journal-title":"J Am Acad Dermatol"},{"key":"679_CR34","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1016\/j.jid.2019.05.016","volume":"139","author":"KB Gordon","year":"2019","unstructured":"Gordon KB, Armstrong AW, Foley P, Song M, Shen Y-K, Li S, Mu\u00f1oz-El\u00edas EJ, Branigan P, Liu X, Reich K. Guselkumab efficacy after withdrawal is associated with suppression of serum IL-23-regulated IL-17 and IL-22 in psoriasis: VOYAGE 2 study. J Investig Dermatol. 2019;139:2437-2446.e1. https:\/\/doi.org\/10.1016\/j.jid.2019.05.016.","journal-title":"J Investig Dermatol"},{"key":"679_CR35","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1111\/bjd.13551","volume":"172","author":"R Bissonnette","year":"2015","unstructured":"Bissonnette R, Iversen L, Sofen H, Griffiths CEM, Foley P, Romiti R, Bachinsky M, Rottinghaus ST, Tan H, Proulx J, Valdez H, Gupta P, Mallbris L, Wolk R. Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial. Br J Dermatol. 2015;172:1395\u2013406. https:\/\/doi.org\/10.1111\/bjd.13551.","journal-title":"Br J Dermatol"},{"key":"679_CR36","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jaad.2015.03.049","volume":"73","author":"K Papp","year":"2015","unstructured":"Papp K, Reich K, Leonardi CL, Kircik L, Chimenti S, Langley RGB, Hu C, Stevens RM, Day RM, Gordon KB, Korman NJ, Griffiths CEM. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). J Am Acad Dermatol. 2015;73:37\u201349. https:\/\/doi.org\/10.1016\/j.jaad.2015.03.049.","journal-title":"J Am Acad Dermatol"},{"key":"679_CR37","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/S0140-6736(21)00126-4","volume":"397","author":"KB Gordon","year":"2021","unstructured":"Gordon KB, Foley P, Krueger JG, Pinter A, Reich K, Vender R, Vanvoorden V, Madden C, White K, Cioffi C, Blauvelt A. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial. Lancet. 2021;397:475\u201386. https:\/\/doi.org\/10.1016\/S0140-6736(21)00126-4.","journal-title":"Lancet"},{"key":"679_CR38","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.jaad.2020.03.031","volume":"82","author":"M Lebwohl","year":"2020","unstructured":"Lebwohl M, Rivera-Oyola R, Murrell DF. Should biologics for psoriasis be interrupted in the era of COVID-19? J Am Acad Dermatol. 2020;82:1217\u20138. https:\/\/doi.org\/10.1016\/j.jaad.2020.03.031.","journal-title":"J Am Acad Dermatol"},{"key":"679_CR39","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1177\/247553031016a00205","volume":"16","author":"M Kamaria","year":"2010","unstructured":"Kamaria M, Liao W, Koo JY. How long does the benefit of biologics last? An update on time to relapse and potential for rebound of biologic agents for psoriasis. Psoriasis Forum. 2010;16:36\u201342.","journal-title":"Psoriasis Forum"},{"key":"679_CR40","doi-asserted-by":"publisher","first-page":"2998","DOI":"10.1097\/CM9.0000000000001232","volume":"133","author":"X-Y Wang","year":"2020","unstructured":"Wang X-Y, Zhang C-L, Wang W-H. Time to relapse after treatment withdrawal for different biologics used to treat plaque psoriasis. Chin Med J (Engl). 2020;133:2998\u20133000. https:\/\/doi.org\/10.1097\/CM9.0000000000001232.","journal-title":"Chin Med J (Engl)"},{"key":"679_CR41","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1111\/bjd.18225","volume":"181","author":"F Bellinato","year":"2019","unstructured":"Bellinato F, Girolomoni G, Gisondi P. Relapse of psoriasis in patients who asked to discontinue etanercept after achieving a stable clinical remission. Br J Dermatol. 2019;181:1319\u201320. https:\/\/doi.org\/10.1111\/bjd.18225.","journal-title":"Br J Dermatol"},{"issue":"2","key":"679_CR42","first-page":"AB190","volume":"56","author":"A Giunta","year":"2007","unstructured":"Giunta A, Papoutsaki M, Bianchi L, Chimenti S. Efficacy and safety of infliximab in long-term treatment of plaque-type psoriasis: a comparative retrospective study on two different (continuous vs. relapse related) regimens P2765. J Am Acad Dermatol. 2007;56(2):AB190.","journal-title":"J Am Acad Dermatol"},{"key":"679_CR43","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1111\/1346-8138.12353","volume":"40","author":"Y Umezawa","year":"2013","unstructured":"Umezawa Y, Nobeyama Y, Hayashi M, Fukuchi O, Ito T, Saeki H, Nakagawa H. Drug survival rates in patients with psoriasis after treatment with biologics. J Dermatol. 2013;40:1008\u201313. https:\/\/doi.org\/10.1111\/1346-8138.12353.","journal-title":"J Dermatol"},{"key":"679_CR44","doi-asserted-by":"publisher","first-page":"e65","DOI":"10.1111\/jdv.16809","volume":"35","author":"R Rivera","year":"2021","unstructured":"Rivera R, Martorell A, L\u00f3pez A, Salgado L, Sahuquillo A, de la Cueva P, Herranz P, Rat\u00f3n JA, Ferr\u00e1n M, Izu R, Ruiz-Genao D, Garc\u00eda-Donoso C, Carrascosa JM. Maintenance of response following discontinuation of guselkumab and secukinumab in Spanish patients who participated in the ECLIPSE study. J Eur Acad Dermatol Venereol. 2021;35:e65\u20137. https:\/\/doi.org\/10.1111\/jdv.16809.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"679_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.01.035","author":"H-Y Chiu","year":"2019","unstructured":"Chiu H-Y, Hui RC-Y, Tsai T-F, Chen Y-C, Chang Liao N-F, Chen P-H, Lai P-J, Wang T-S, Huang Y-H. Predictors of time to relapse following ustekinumab withdrawal in patients with psoriasis who had responded to therapy: an eight-year multicenter study. J Am Acad Dermatol. 2019. https:\/\/doi.org\/10.1016\/j.jaad.2019.01.035.","journal-title":"J Am Acad Dermatol"},{"key":"679_CR46","unstructured":"Down-titration and discontinuation strategies of tumour necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity\u2014PubMed, (n.d.). https:\/\/pubmed.ncbi.nlm.nih.gov\/31125448\/ (Accessed Feb 4, 2022)."}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-022-00679-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-022-00679-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-022-00679-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T07:09:53Z","timestamp":1744700993000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-022-00679-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,30]]},"references-count":46,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["679"],"URL":"https:\/\/doi.org\/10.1007\/s40257-022-00679-y","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.742110126.793596115","asserted-by":"object"}]},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,30]]},"assertion":[{"value":"22 February 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"MMR has received grants or personal fees from AbbVie, Lilly, Janssen, UCB, and Leo Pharma. MT is a speaker for Janssen. CP has received grants and personal fees from Amgen, AbbVie, Celgene, Eli Lilly, Novartis, Janssen, Pfizer, and Leo Pharma. JS and FJ have no conflicts of interest to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Yes.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and materials"}},{"value":"On demand.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"MMR, JS, and CP performed the literature research and the analysis of the data. All the authors participated in the interpretation of the results and in the writing of the manuscript.","order":10,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}